[1]Ford AC,Forman D,Hunt RH,et al.Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials[J].BMJ,2014,348(16): g3174. [2]杨飞,邓跃华,刘传磊,等.HSP gp96与Jab1在胃癌中的表达及其临床意义[J].安徽医科大学学报,2013,48(9):1107-1110. [3]胡华.端粒蛋白TRF2、TIN2、TERT、Ku70和端粒长度与胃癌发生发展的关系[D].南华大学,2014. [4]陈晓兵.胃癌患者幽门螺杆菌感染情况与肿瘤恶性程度的相关性研究[J].海南医学院学报,2017,23(4): 4. [5]Yoshida T,Kato J,Inoue I,et al.Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer[J].Int J Cancer,2014,134(6): 1445-1457. [6]Pan Y,Wang S,Su B,et al.Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression[J].Oncogene,2017,36(8): 1069-1079. [7]杨飞,邓跃华,刘传磊,等.HSP gp96与Jab1在胃癌中的表达及其临床意义[J].安徽医科大学学报,2013,48(9): 1107-1110. [8]周建斌,胡华,盛顺良,等.端粒蛋白TRF1,TRF2和TIN2 在宫颈鳞癌中的表达及意义[J].中南医学科学杂志,2013,41(2): 124-126. [9]李多,于永强,齐维娟,等.幽门螺杆菌感染和细胞周期蛋白 D1 蛋白表达与胃癌的相关性研究[J].中国临床医生,2016,16 (7): 45-48. [10]王建馗,张福林.幽门螺杆菌感染与胃癌化疗疗效的关系[J].世界华人消化杂志,2014,22(13): 1867-1870. [11]张曙云,陈渠通,葛晴川,等.幽门螺杆菌感染程度与胃蛋白酶原和胃癌相关肿瘤标志物的关系[J].国际检验医学杂志,2016,37(23): 3298-3299. [12]李帅,翟二涛,王文胜,等.JAB1在胃癌组织中的表达及临床意义[J].消化肿瘤杂志:电子版,2013,5(2):88-91. [13]Sarek G,Vannier J B,Panier S,et al.TRF2 recruits RTEL1 to telomeres in S phase to promote t-loop unwinding[J].Mol Cell,2015,57(4): 622-635. [14]吴军,郑海燕,张志广,等.Hp 感染与胃癌组织 HIF-1α 表达相关性及生物学意义的研究[J].中华肿瘤防治杂志,2013 ,20(6): 416-419. [15]Bartocci C,Lazzerini Denchi E.Put a RING on it: regulation and inhibition of RNF8 and RNF168 RING finger E3 ligases at DNA damage sites[J].Front Genet,2013,4:128.
2017, Vol. 34 
